Cargando…

Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia

BACKGROUND: UCART19 is an “off-the-shelf” genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells. METHODS: UCART19 was administered to 25 adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dupouy, Sandra, Marchiq, Ibtissam, Derippe, Thibaud, Almena-Carrasco, Maria, Jozwik, Agnieszka, Fouliard, Sylvain, Adimy, Yasmina, Geronimi, Julia, Graham, Charlotte, Jain, Nitin, Maus, Marcela V., Mohty, Mohamad, Boissel, Nicolas, Teshima, Takanori, Kato, Koji, Benjamin, Reuben, Balandraud, Svetlana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035397/ https://www.ncbi.nlm.nih.gov/pubmed/36970059 http://dx.doi.org/10.1158/2767-9764.CRC-22-0175

Ejemplares similares

Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia
por: Derippe, Thibaud, et al.
Publicado: (2022)

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
por: Graham, Charlotte Elizabeth, et al.
Publicado: (2021)

P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
por: Boissel, Nicolas, et al.
Publicado: (2023)

P1420: PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES
por: Aranda Orgilles, B., et al.
Publicado: (2022)

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
por: Marchiq, Ibtissam, et al.
Publicado: (2015)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
por: Jain, N., et al.
Publicado: (2022)

Knock out of the BASIGIN/CD147 chaperone of lactate/H+ symporters disproves its pro-tumour action via extracellular matrix metalloproteases (MMPs) induction
por: Marchiq, Ibtissam, et al.
Publicado: (2015)

Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status
por: Granja, Sara, et al.
Publicado: (2014)

Metabolic Plasiticy in Cancers—Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs
por: Ždralević, Maša, et al.
Publicado: (2017)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma
por: Scarfò, Irene, et al.
Publicado: (2019)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Making CAR T Cells a Solid Option for Solid Tumors
por: Schmidts, Andrea, et al.
Publicado: (2018)

Optimized Protocol for the In Situ Derivatization of Glutathione with N-Ethylmaleimide in Cultured Cells and the Simultaneous Determination of Glutathione/Glutathione Disulfide Ratio by HPLC-UV-QTOF-MS
por: Sun, Xueni, et al.
Publicado: (2020)

High antigen density of BCMA: friend or foe to CAR T cells?
por: Gaballa, Mahmoud R, et al.
Publicado: (2022)

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
por: Metelo, Ana M., et al.
Publicado: (2022)

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
por: Scarfò, Irene, et al.
Publicado: (2017)

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients
por: Haderbache, Rafik, et al.
Publicado: (2021)

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells
por: Bai, Zhiliang, et al.
Publicado: (2021)

Influence of the Duration of Intravenous Drug Administration on Tumor Uptake
por: Fouliard, Sylvain, et al.
Publicado: (2013)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays
por: Wang, Xiao, et al.
Publicado: (2019)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
por: Gill, Saar, et al.
Publicado: (2022)

Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells
por: Pourzia, Alexandra L., et al.
Publicado: (2023)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

Did COVID-19 Push CAR-T to the Outpatient Setting?
por: Harris, Alyssa, et al.
Publicado: (2022)

Changes in Eating Behaviors during the COVID-19 Lockdown and the Impact on the Potential Inflammatory Effects of Diet
por: Montero López, María del Pilar, et al.
Publicado: (2022)

Reactivated world war two traumatic memories in COVID‐19 lockdown period
por: Bigarré, Inès, et al.
Publicado: (2020)

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
por: Sheih, Alyssa, et al.
Publicado: (2020)

Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
por: Laurent, Elisabeth, et al.
Publicado: (2021)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

One Year into the COVID-19 Pandemic
por: Mohty, Mohamad, et al.
Publicado: (2021)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ae451djvhr50dn8r076r5o5h0a